1. Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia 
G. Kees Hovingh, MD, PhD, MBA, John R. Guyton, MD, Gisle Langslet, MD, Robert Dufour, MD, MSc, CSPQ, Marie T. Baccara-Dinet, MD, MSc, Chantal Din-Bell, MSc, Garen Manvelian, MD, Michel Farnier, MD, PhD 
Journal of Clinical Lipidology 
Volume 12, Issue 6, Pages (November 2018)
DOI: /j.jacl
Copyright © 2018 National Lipid Association Terms and Conditions

2. Journal of Clinical Lipidology 2018 12, 1463-1470DOI: (10.1016/j.jacl.2018.08.011)
Copyright © 2018 National Lipid Association Terms and Conditions

3. Figure 1
OLE study design. †Patients enrolled from HIGH FH were not included in this analysis as they started OLE on alirocumab 150 mg Q2W, with no dose adjustment during the study duration. ‡To be performed 2 weeks after the last injection for the patients who completed the study or within 5 days after treatment discontinuation. §To be performed 10 weeks after the last injection. During the double-blind treatment period of FH I and FH II, patients received alirocumab 75 mg or 150 mg Q2W or placebo. During the double-blind treatment period of LONG TERM and HIGH FH, patients received alirocumab 150 mg Q2W or placebo. Patients who completed FH I, FH II, and LONG TERM started OLE with alirocumab 75 mg Q2W, which could be increased to 150 mg Q2W after week 12. Patients from HIGH FH began OLE with alirocumab 150 mg Q2W (but were not included in the present analysis). HeFH, heterozygous familial hypercholesterolemia; LLT, lipid-lowering therapy; NCEP ATP III TLC, National Cholesterol Education Program Adult Treatment Panel III Therapeutic Lifestyle Changes; OLE, open-label extension; Q2W, every 2 weeks; W, week.
Journal of Clinical Lipidology  , DOI: ( /j.jacl )
Copyright © 2018 National Lipid Association Terms and Conditions